Skip to content
ContentLora

    Tip: press / anywhere to search.

    Explainer

    Factor XIa blood thinners explained

    Factor XIa inhibitors are a new class of blood thinners that target factor XI, a clotting protein that reviewers call a leading anticoagulant target of the past decade.[1] The hope is to prevent clots while sparing the body's normal clotting, and in November 2026 the FDA approved the first one, asundexian (Sunharbo), to reduce the risk of another stroke.[2][3] Results so far differ by condition: asundexian helped after stroke but was inferior to apixaban in atrial fibrillation, and a milvexian trial after acute coronary syndrome was stopped for futility.[4][5][6]

    Editor reviewedStrict sourcingUpdated Explainer16 claims · 100% primaryHealth and medicine

    Factor XIa inhibitors are blood thinners that block factor XIa, the activated form of a clotting protein called factor XI. A 2026 review describes factor XI as having emerged as a leading new anticoagulant target over the past decade.[1] On 9 November 2026 the FDA approved the first of them, asundexian (Sunharbo).[3]

    This page is not medical advice. Decisions about blood thinners should be made with a doctor.

    Why a new kind of blood thinner

    Existing blood thinners, such as warfarin and direct oral anticoagulants like apixaban and rivaroxaban, prevent clots and lower stroke risk, but they carry a risk of bleeding, so not everyone can use them.[7] Reviewers say factor XIa inhibition promises anticoagulant effect while sparing normal clotting. They point to people who have had a non-cardioembolic ischaemic stroke, who remain at substantial risk of another stroke on antiplatelet drugs but for whom conventional anticoagulants carry too high a bleeding risk.[2]

    Where they have worked

    The clearest success is in preventing a second stroke. In the phase 3 OCEANIC-STROKE trial, the FDA said asundexian cut the risk of ischaemic stroke by 26% compared with placebo, with both groups also on antiplatelet therapy.[8][9] A 2026 review reported the benefit was consistent across stroke subtypes, with no excess of major bleeding or bleeding in the brain.[4] The FDA said major bleeding was higher with asundexian in people over 75 and in the first 90 days, and that gastrointestinal bleeding was more common.[10] Earlier phase 2 stroke trials of asundexian and milvexian had looked safe but showed no effect on brain-scan measures. Reviewers say this showed that silent brain infarcts are a poor stand-in for real outcomes.[11]

    Where they have not

    Results have differed by condition. In atrial fibrillation, asundexian was inferior to apixaban in the OCEANIC-AF trial, and a 2026 review attributed this to the dose, the comparator and the setting.[5] Abelacimab, an antibody, reduced major and clinically relevant non-major bleeding by 62% compared with rivaroxaban in atrial fibrillation. Reviewers say its effect on preventing clots and strokes has not been established.[12] After acute coronary syndrome, the LIBREXIA-ACS trial of milvexian was stopped early for futility. Milvexian did not reduce cardiovascular death, heart attack or ischaemic stroke, though it did not increase brain or fatal bleeding.[6]

    What reviewers conclude

    One 2026 review concluded that the evidence supports factor XIa inhibitors for particular uses, such as cancer-associated thrombosis, secondary stroke prevention and people at high bleeding risk. It found weaker support for broadly replacing direct oral anticoagulants.[13] Another review said factor XI may matter more for arterial clots in some conditions than others, and that the best drug, dose and patients are still to be worked out.[14] Reviewers also say a class effect still needs confirming in further trials, along with how long to treat and whether deeper inhibition helps.[15]

    What to watch

    Milvexian has a three-trial phase 3 programme, which will add to the evidence on whether the stroke benefit applies across the class.[16][15] For related conditions, see stroke explained and atrial fibrillation explained.

    Asundexian (Sunharbo)

    Asundexian (Sunharbo) is Bayer's factor XIa blood thinner, approved by the FDA in November 2026 to lower the risk of another stroke.

    More in Health & medicine

    Questions readers ask

    What is a factor XIa inhibitor?

    A blood thinner that blocks factor XIa, the activated form of the clotting protein factor XI. Reviewers describe factor XI as a leading new anticoagulant target of the past decade.[1]

    Why are doctors interested in them?

    Reviewers say factor XIa inhibition promises to prevent clots while sparing normal clotting. That matters for people such as stroke survivors, for whom conventional anticoagulants carry too high a bleeding risk.[2]

    Has any been approved?

    Yes. On 9 November 2026 the FDA approved asundexian (Sunharbo), the first factor XIa inhibitor, for use with antiplatelet therapy after a recent non-cardioembolic ischaemic stroke or high-risk TIA.[3]

    Do they replace drugs like apixaban?

    Not on current evidence. Asundexian was inferior to apixaban in atrial fibrillation, and a 2026 review found weaker support for broadly replacing direct oral anticoagulants.[5][13]

    Which other factor XI drugs are being tested?

    Milvexian, which has a three-trial phase 3 programme, and abelacimab, an antibody. One milvexian trial after acute coronary syndrome was stopped for futility in 2026.[16][12][6]

    Sources

    · 16 claims from 6 publishers

    Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.

    1. [1]

      A 2026 review describes factor XI and its activated form, factor XIa, as having emerged over the past decade as a leading new target for anticoagulant drugs. confirmedas of 2026-06-25

    2. [2]

      Reviewers note that people with non-cardioembolic ischaemic stroke face a substantial risk of another stroke despite antiplatelet drugs, that conventional anticoagulants carry too high a bleeding risk for them, and that factor XIa inhibition promises anticoagulant effect while sparing normal blood clotting (haemostasis). confirmedas of 2026-10-27

    3. [3]

      On 9 November 2026 the FDA approved Sunharbo (asundexian), the first factor XIa inhibitor, for use with antiplatelet therapy to reduce the risk of stroke in adults after a recent mild-to-moderate non-cardioembolic ischaemic stroke or a high-risk transient ischaemic attack (TIA). confirmedas of 2026-11-09

    4. [4]

      A 2026 review of OCEANIC-STROKE reported that asundexian added to single or dual antiplatelet therapy reduced recurrent ischaemic stroke consistently across stroke subtypes, without an excess of major bleeding or intracranial haemorrhage. confirmedas of 2026-10-27

    5. [5]

      In the earlier OCEANIC-AF trial, asundexian was inferior to apixaban for stroke prevention in atrial fibrillation; a 2026 review attributed this to the dose, the comparator and the setting. confirmedas of 2026-10-27

    6. [6]

      The LIBREXIA-ACS trial was stopped early for futility; milvexian added to antiplatelet therapy after acute coronary syndrome did not reduce cardiovascular death, heart attack or ischaemic stroke, though it did not increase intracranial or fatal bleeding. confirmedas of 2026-11-13

    7. [7]

      Blood thinners, such as warfarin or the direct-acting oral anticoagulants (DOACs) apixaban, dabigatran, rivaroxaban and edoxaban, prevent clots and lower stroke risk, but they carry a risk of bleeding, so not everyone can use them. confirmedas of 2026-11-07

    8. [8]

      The FDA said asundexian reduced the risk of ischaemic stroke by 26% compared with placebo over a median treatment period of 14.2 months in OCEANIC-STROKE. confirmedas of 2026-11-09

    9. [9]

      The approval was based on OCEANIC-STROKE, a randomized, double-blind, placebo-controlled phase 3 trial of 12,327 adults who started asundexian or placebo within 72 hours of a non-cardioembolic ischaemic stroke or high-risk TIA; both groups also received antiplatelet therapy. confirmedas of 2026-11-09

    10. [10]

      According to the FDA, the overall rate of major bleeding was similar with asundexian and placebo but was higher with asundexian in patients older than 75 and during the first 90 days, and gastrointestinal bleeding was more common with asundexian. confirmedas of 2026-11-09

    11. [11]

      Phase 2 trials of asundexian and milvexian in stroke were reassuring on safety but neutral on brain-imaging endpoints, which reviewers say showed that silent (covert) infarcts are a poor stand-in for clinical outcomes. confirmedas of 2026-10-27

    12. [12]

      In atrial fibrillation, the antibody abelacimab reduced major and clinically relevant non-major bleeding by 62% compared with rivaroxaban in the AZALEA-TIMI 71 trial, though reviewers say its effect on preventing clots and strokes has not been established. confirmedas of 2026-10-27

    13. [13]

      A 2026 review concluded that the evidence supports using factor XIa inhibitors for particular indications, such as cancer-associated thrombosis, secondary stroke prevention and people at high bleeding risk, but gives weaker support for broadly replacing direct oral anticoagulants. confirmedas of 2026-06-25· interpretation

    14. [14]

      Reviewers say the contribution of factor XI to arterial clots may vary across clinical indications, and that the specific drug, dose and patient selection remain to be optimised. confirmedas of 2026-11-13

    15. [15]

      Reviewers say confirmation of a class effect from further trials is still awaited, along with questions about treatment duration, deeper inhibition and use in other cardiovascular conditions. confirmedas of 2026-10-27

    16. [16]

      Milvexian entered a three-trial phase 3 programme. confirmedas of 2026-06-25

    Revision history (1)
    1. Page created.

    Created Nov 14, 2026. Last reviewed by an editor on Nov 15, 2026. Next scheduled review: Nov 14, 2027.

    Cite this page

    "Factor XIa blood thinners explained." ContentLora, updated Nov 14, 2026. https://contentlora.com/explain/factor-xia-inhibitors-explained

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.